AstraZeneca: Breast Neoplasms trials

The registry lists 198 Breast Neoplasms studies with AstraZeneca as lead sponsor. 20 are open to participants now and 41 have results posted.

Phase 1 42Phase 2 43Phase 3 46Phase 4 7No phase 72(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)CompletedNCT04553926
• A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833CompletedNCT04546347Phase 1
• A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerCompletedNCT04541433Phase 1
• A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive, not recruitingNCT04538742Phase 1/2
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibActive, not recruitingNCT04421963Phase 3
• Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCActive, not recruitingNCT03997123Phase 3
• A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
• To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.WithdrawnNCT03658213Phase 3
• Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
• Lynparza Breast Cancer Clinical Experience InvestigationCompletedNCT03590938
• ALEXANDRIA Study EgyptCompletedNCT03583463
• Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.CompletedNCT03236974Phase 1
• AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1
• International Breast Cancer Biomarker,Standard of Care and Real World Outcomes StudyCompletedNCT03078036
• Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in AlgeriaCompletedNCT02733601
• Cancer in Patients on Dapagliflozin and Other Antidiabetic TreatmentCompletedNCT02695121
• Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast CancerCompletedNCT02599714Phase 1
• A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1
• Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid TumoursCompletedNCT02260661Phase 1
• AZD9496 First Time in Patients Ascending Dose StudyCompletedNCT02248090Phase 1
• Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor TumorsCompletedNCT02144051Phase 1
• Management of Metastatic Breast Cancer in Clinical Practice - Retrospective StudyCompletedNCT01715155
• Epidemiology and Management of Metastatic Breast CancerCompletedNCT01711502
• Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin TreatmentTerminatedNCT01596530Phase 1
• LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast CancerCompletedNCT01561443
• Faslodex Specific Clinical Experience InvestigationCompletedNCT01501266
• Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg TreatmentTerminatedNCT01425294
• Patterns of Care in Hormone-receptor Positive, Advanced Breast CancerTerminatedNCT01277926
• Reasons for Changing HOrmonal Therapy of Advanced Breast CancerCompletedNCT01265654
• Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesCompletedNCT01226316Phase 1
• A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerCompletedNCT01171417
• Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) TreatmentCompletedNCT01144572
• Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment AdherenceCompletedNCT01081509
• Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.CompletedNCT01003158Phase 1
• Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)CompletedNCT00944918Phase 3
• Arimidex Therapy Compliance Electronic Monitoring SystemCompletedNCT00936442
• Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With ChemotherapyWithdrawnNCT00888082Phase 3
• 10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)CompletedNCT00885612
• Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast CancerCompletedNCT00884143
• Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)CompletedNCT00880711
• Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast CancerCompletedNCT00878930
• Faslodex Post Marketing SurveillanceCompletedNCT00860561
• Retrospective Survey of Bone Fracture in Patients With Arimidex 1mgCompletedNCT00859560
• Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)CompletedNCT00857012
• ATAC - Arimidex, Tamoxifen Alone or in CombinationCompletedNCT00849030Phase 3
• ATAC - Endometrial Sub-ProtocolCompletedNCT00814125Phase 3
• ATAC - Pharmacokinetics (PK) Sub-ProtocolCompletedNCT00784862Phase 3
• The Performance of Patient Support Program in Early Stage Breast CancerCompletedNCT00769080
• An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily PracticeCompletedNCT00767585
• An Observational Study of Adherence to Anastrozole in Early Breast Cancer TreatmentCompletedNCT00737009
• Faslodex Registry: Fulvestrant in Current Clinical PracticeCompletedNCT00735215
• Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer PatientsCompletedNCT00727883
• Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerCompletedNCT00707707Phase 1
• National Survey on Infiltrative Breast CancerCompletedNCT00696527
• Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast CancerCompletedNCT00692289
• Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in FranceCompletedNCT00681369
• CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)CompletedNCT00681122
• Retrospective Brazilian Study of Fulvestrant in Advanced Breast CancerCompletedNCT00660803
• Quality Of Life While Receiving FaslodexCompletedNCT00643513
• Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast CancerCompletedNCT00638391
• Ph II Early BC Pre-Surgical Biologic StudyCompletedNCT00637026Phase 2
• Second Line Breast Cancer TrialCompletedNCT00635713Phase 3
• IRESSA™ (Gefitinib) in Breast Cancer PatientsCompletedNCT00632723Phase 2
• A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast CancerWithdrawnNCT00627627Phase 1/2
• Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With AnastrozoleCompletedNCT00623519
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedNCT00600496Phase 1
• Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast CancerCompletedNCT00562458
• Electronic Study for Anastrozole Pharmacovigilance EvaluationCompletedNCT00558168
• Patient's Anastrozole Compliance to Therapy ProgrammeTerminatedNCT00555867
• A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00544986Phase 4
• Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant TherapyTerminatedNCT00542594
• APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)CompletedNCT00523315
• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelCompletedNCT00516724Phase 1
• Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
• Faslodex 500mg Multiple Dose Tolerability Study in BC PatientsCompletedNCT00328120Phase 1
• Faslodex Advanced Breast Cancer Local Chinese StudyCompletedNCT00327769Phase 3
• Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast CancerCompletedNCT00319618Phase 2
• Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal PatientsCompletedNCT00303524Phase 2
• 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast CancerCompletedNCT00300508Phase 3
• ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.CompletedNCT00291759Phase 3
• Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.CompletedNCT00287534Phase 2
• ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 YearsCompletedNCT00286117Phase 3
• SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast CancerCompletedNCT00272740Phase 2
• Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa StudyCompletedNCT00255463Phase 2
• A Study of ZD1839 Effects on Cell Proliferation in Breast CancerWithdrawnNCT00252811Phase 2
• ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast CancerCompletedNCT00247481Phase 2
• Arimidex Observational: Reason for and Effect of Change From TamoxifenCompletedNCT00246961
• Faslodex Observations During Regular Use by Advanced Mammacarcinoma PatientsTerminatedNCT00241462
• A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast CancerCompletedNCT00241449Phase 3
• Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast CancerCompletedNCT00239343Phase 2
• Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus ZoladexCompletedNCT00235937Phase 2
• A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast CancerCompletedNCT00234403Phase 2
• PROACT - Pre-Operative Arimidex Compared To TamoxifenCompletedNCT00232661Phase 3
• Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa StudyCompletedNCT00229697Phase 2
• Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast CancerCompletedNCT00093002Phase 2
• Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast CancerCompletedNCT00082277Phase 4
• Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast CancerCompletedNCT00077025Phase 2
• The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast CancerCompletedNCT00065325Phase 3